Nanomaterials · 2022 · 14 citations · 25 references
MedicineOncologyPharmacologyChemotherapyDrug DeliveryNanoparticle Drug DeliveryCancer ImmunotherapyCancer NanomedicineLipid-based NanoparticlesNanocarriers For TherapeuticsNanomedicineTargeted TherapyAnticancer Drug LoadingCancer NanotherapyCombination Drug LoadingCombination Drug TherapyNanoemulsion SystemsNanoemulsionsNanoparticle-based ImmunotherapyTumor-targeted Drug Delivery
High-grade melanoma remains a major life-threatening illness despite the improvement in therapeutic control that has been achieved by means of targeted therapies and immunotherapies in recent years. This work presents a preclinical-level test of a multi-pronged approach that includes the loading of immunotherapeutic (ICOS-Fc), targeted (sorafenib), and chemotherapeutic (temozolomide) agents within Intralipid®, which is a biocompatible nanoemulsion with a long history of safe clinical use for total parenteral nutrition. This drug combination has been shown to inhibit tumor growth and angiogenesis with the involvement of the immune system, and a key role is played by ICOS-Fc. The inhibition of tumor growth in subcutaneous melanoma mouse models has been achieved using sub-therapeutic drug doses, which is most likely the result of the nanoemulsion’s targeting properties. If translated to the human setting, this approach should therefore allow therapeutic efficacy to be achieved without increasing the risk of toxic effects.
25
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder, Vladimir Makarov, Taha Merghoub et al. · New England Journal of Medicine · 2014 · 4.4K citations · Full text
Medicine, Immunology, Oncology +17
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov et al. · Cell · 2017 · 2.6K citations · Full text
Medicine, Immunology, Oncology +12
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Andreas Hutloff, Anna‐Maria Dittrich, Katja C. Beier et al. · Nature · 1999 · 1.5K citations
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Martin Oft · Cancer Immunology Research · 2014 · 298 citations · Full text
Medicine, Immunology, Oncology +17